NCT01926015View on ClinicalTrials.gov

Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)

PHASE4CompletedINTERVENTIONAL

Enrollment

192

Participants

Timeline

Start Date

September 19, 2013

Primary Completion Date

June 6, 2014

Study Completion Date

June 6, 2014

Conditions

Rotavirus Disease

Interventions

BIOLOGICAL

RotaTeq™ (V260)

Live, oral, pentavalent vaccine containing 5 human-bovine reassortant rotavirus strains

BIOLOGICAL

DTP-IPV

Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01926015 - Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) | Biotech Hunter | Biotech Hunter